# Casdatifan

Type: Product

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/casdatifan
Canonical HTML page: https://gethealthbrief.com/entity/casdatifan

## Recent coverage (1 stories)

### 127-Patient Trial of Casdatifan Shows Durable Responses in Advanced Kidney Cancer
2026-07-28 03:57:34 · Sentiment: Bullish · Impact: 7/10 · Sources: 2

A phase 1 trial of the oral HIF-2α inhibitor casdatifan in 127 heavily pretreated ccRCC patients demonstrated durable tumor responses and a manageable safety profile. The findings, published in Nature, may guide future biomarker-based treatment strategies, potentially reducing futile therapies and optimizing resource use in oncology care.
Full story: https://gethealthbrief.com/story/casdatifan-kidney-cancer-trial-health

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.